SCHEMBL1478735

SCHEMBL1478735

N#Cc1cncc(/C=C/c2ccc(Cl)cc2)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAF1 P04049 2/20 0.57
AHR P35869 1/20 0.44
AURKA O14965 1/20 0.38
KDR P35968 1/20 0.38
ALOX5 P09917 1/20 0.38
PTGS1 P23219 1/20 0.38
PTGS2 P35354 1/20 0.38
KDM4E B2RXH2 2/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
MAOB P27338 2/20 0.37
MAOA P21397 1/20 0.37
ALDH1A1 P00352 1/20 0.36
CYP1A2 P05177 1/20 0.36
MAPK1 P28482 1/20 0.36
HSD17B10 Q99714 1/20 0.36
MAPT P10636 1/20 0.36
SRC P12931 2/20 0.36
AKT1 P31749 1/20 0.36
CYP11B1 P15538 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1478736 1.00 RAF1 (0.57) RAF1AHRAURKAKDRALOX5
SCHEMBL1476571 0.83 RAF1 (0.57) RAF1AURKAKDRPTGS1MAPT
SCHEMBL1476572 0.83 RAF1 (0.57) RAF1AURKAKDRPTGS1MAPT
SCHEMBL1476900 0.83 RAF1 (0.65) RAF1AURKAKDRKDM4EALDH1A1
SCHEMBL1476902 0.83 RAF1 (0.65) RAF1AURKAKDRKDM4EALDH1A1
SCHEMBL1477161 0.83 RAF1 (0.61) RAF1MAOBMAOACYP1A2
SCHEMBL1477163 0.83 RAF1 (0.61) RAF1MAOBMAOACYP1A2
SCHEMBL1477223 0.80 RAF1 (0.57) RAF1AURKAKDRKDM4ENPC1
SCHEMBL1477221 0.80 RAF1 (0.57) RAF1AURKAKDRKDM4ENPC1
SCHEMBL1477004 0.78 RAF1 (0.68) RAF1MAOBMAOAAKT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7915424-B2 Analgesics; anxiolytic agents ELI LILLY AND COMPANY (US) 2011-03-29 US disclosed
EP-1729771-B1 PYRIDYL DERIVATIVES AND THEIR USE AS MGLU5 RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2009-10-14 EP disclosed
US-20080194647-A1 Pyridyl Derivatives and Their Use as Mglu5 Antagonists ELI LILLY AND COMPANY (US) 2008-08-14 US disclosed
EP-1729771-A1 PYRIDYL DERIVATIVES AND THEIR USE AS MGLU5 RECEPTOR ANTAGONISTS Eli Lilly & Company (US) 2006-12-13 EP disclosed
WO-2005094822-A1 PYRIDYL DERIVATIVES AND THEIR USE AS MGLU5 RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2005-10-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194647-A1 Pyridyl Derivatives and Their Use as Mglu5 Antagonists HRH4, CNR2, CNR1 RAF1 4597/4885AHR 364/4885AURKA 3887/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.